Correction: Opiant Pharmaceuticals Corrects Error in Issuing Duplicate Press Release Today
January 20 2022 - 5:45PM
Correction: Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”)
(NASDAQ: OPNT), a specialty pharmaceutical company developing
medicines to treat addictions and drug overdose, reports that the
company mistakenly reissued the press release this afternoon
entitled, "Opiant Reports Inducement Grants Under Nasdaq Listing
Rule 5635(c)(4)." This press release is a duplicate of the press
release issued on December 20, 2021. The company regrets the error.
For Media and Investor Inquiries:Ben Atkins, Opiant(310)
598-5410batkins@opiant.com
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Sep 2023 to Sep 2024